Deals Shaping the Medical Industry, December 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
You may also be interested in...
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Denmark’s specialty dermatology company, Leo Pharma, has globalized its infrastructure and is now investing in its internally and externally sourced product pipeline to help it compete with big pharma companies keen to move into the therapeutic area.
BeiGene and Novartis penned a potential $2.2bn collaboration for the development, manufacture, and commercialization of BeiGene’s humanized IgG4 anti-PD-1 monoclonal antibody tislelizumab in the US, Canada, Mexico, member countries of the EU, the UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. Steris entered into a definitive agreement to acquire Cantel Medical, a global provider of infection prevention products and services primarily to endoscopy and dental customers. The total enterprise value of the deal is estimated at $4.6bn. Financing reached $10.5bn in biopharma, $984m in device, and $2.7bn in diagnostics.